Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China · Delayed Price · Currency is CNY 28.84
-0.44 (-1.50%)
Oct 22, 2025, 3:00 PM CST
Shanghai Fosun Pharmaceutical (Group) Employees
Shanghai Fosun Pharmaceutical (Group) had 40,557 employees as of December 31, 2024. The number of employees increased by 187 or 0.46% compared to the previous year.
Employees
40,557
Change (1Y)
187
Growth (1Y)
0.46%
Revenue / Employee
997.14K CNY
Profits / Employee
80.70K CNY
Market Cap
72.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 40,557 | 187 | 0.46% |
| Dec 31, 2023 | 40,370 | 1,971 | 5.13% |
| Dec 31, 2022 | 38,399 | 2,120 | 5.84% |
| Dec 31, 2021 | 36,279 | 4,021 | 12.47% |
| Dec 31, 2020 | 32,258 | 888 | 2.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aier Eye Hospital Group | 42,693 |
| WuXi AppTec | 39,414 |
| Shenzhen Mindray Bio-Medical Electronics | 21,667 |
| Jiangsu Hengrui Medicine | 20,238 |
| Huadong Medicine | 18,265 |
| Zhejiang NHU Company | 11,369 |
| Yunnan Baiyao Group Co.,Ltd | 9,277 |
| Shanghai United Imaging Healthcare | 8,173 |
Shanghai Fosun Pharmaceutical (Group) News
- 11 days ago - China’s ‘health silk road’ in Africa gets a boost with insulin, pharma projects - South China Morning Post
- 5 weeks ago - Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug - South China Morning Post
- 7 months ago - Shanghai Fosun Pharmaceutical reports FY results - Seeking Alpha
- 2 years ago - Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse - Reuters
- 3 years ago - Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech - Forbes
- 3 years ago - Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal - Seeking Alpha
- 4 years ago - Pandemic Accelerates China's Drive Into mRNA Treatments - Seeking Alpha
- 4 years ago - Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse - Seeking Alpha